Chemexpress(SH:688131) Shenwan Hongyuan Securities·2025-10-31 13:14Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported strong performance in Q3 2025, with revenue of 2.059 billion yuan for the first three quarters, representing a year-on-year growth of 27.18%. The net profit attributable to shareholders reached 237 million yuan, up 65.09% year-on-year, indicating significant improvement in profit quality [4][7] - The front-end life science reagent business is the main growth driver, contributing 70% of total revenue in the first three quarters, with a revenue increase of over 31% [7] - The back-end business, focusing on specialty generic drug APIs and related intermediates, has a solid order backlog exceeding 590 million yuan, reflecting a 40.1% year-on-year increase [7] Financial Data and Profit Forecast - Total revenue is projected to reach 2.815 billion yuan in 2025, with a year-on-year growth rate of 24.0% [6] - The net profit attributable to shareholders is expected to be 321 million yuan in 2025, with a growth rate of 59.4% [6] - The gross margin for the front-end business reached 63.05% in the first half of 2025, an increase of 3.48 percentage points compared to the same period in 2024 [7] Business Development - The company has established a comprehensive service system in the ADC field, with its CDMO base in Chongqing successfully operational and passing EU QP audit [7] - The company is expected to see improved capacity utilization in the back-end business as existing orders are gradually converted into revenue, enhancing overall profitability [7] Valuation and Target Price - The target market capitalization for 2025 is estimated at 20.8 billion yuan, representing an upside potential of 22.62% from the current market value [7]